The incorporation of novel biological agents has become the cornerstone of treatment in multiple myeloma (MM). In this video, Torben Plesner, MD, from the University of Southern Denmark, Vejle, Denmark, discusses the variety of agents used in the therapeutic management of MM. This interview was recorded at the 1st European Myeloma Network (EMN) Meeting, in Turin, Italy.
Managing plasma cell leukemia: Pls, IMiDs, alkylating agents and antibodies
